Attached files
| file | filename |
|---|---|
| 10-K - ANNUAL REPORT - Cellular Biomedicine Group, Inc. | cbmg_10k.htm |
| EX-31 - CERTIFICATION - Cellular Biomedicine Group, Inc. | cbmg_ex31.htm |
| EX-21 - SUBSIDIARIES - Cellular Biomedicine Group, Inc. | cbmg_ex21.htm |
| EX-23.1 - CONSENT - Cellular Biomedicine Group, Inc. | cbmg_ex231.htm |
| EX-23.2 - CONSENT - Cellular Biomedicine Group, Inc. | cbmg_ex232.htm |
| EX-10.39 - CONSULTING AGREEMENT - Cellular Biomedicine Group, Inc. | cbmg_ex1039.htm |
| EX-10.46 - CLINICAL TRIAL AGREEMENT - Cellular Biomedicine Group, Inc. | cbmg_ex1046.htm |
| EX-10.45 - PATENT TRANSFER AGREEMENT - Cellular Biomedicine Group, Inc. | cbmg_ex1045.htm |
| EX-10.43 - TECHNOLOGY TRANSFER CONTRACT - Cellular Biomedicine Group, Inc. | cbmg_ex1043.htm |
Exhibit 32
CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Cellular Biomedicine Group Inc., a Delaware corporation (the "Company"), does hereby certify, to such officer's knowledge, that:
The Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the "Form 10-K") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Dated: March 11, 2016
|
By:
|
/s/ Bizuo (Tony) Liu | |
| Bizuo (Tony) Liu | |||
|
Chief Executive Officer and Chief Financial Officer
|
|||
|
(principal executive officer and financial and accounting officer)
|
The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of Form 10-K or as a separate disclosure document.
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.